Novartis Cash and Equivalents vs. Current Valuation
NVS Stock | USD 95.12 0.76 0.81% |
Cash And Equivalents | First Reported 2010-12-31 | Previous Quarter 5.3 B | Current Value 7.6 B | Quarterly Volatility 1.7 B |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.78 | 0.7327 |
|
| |||||
Net Profit Margin | 0.17 | 0.3183 |
|
| |||||
Operating Profit Margin | 0.18 | 0.2094 |
|
| |||||
Pretax Profit Margin | 0.25 | 0.1955 |
|
| |||||
Return On Assets | 0.11 | 0.1486 |
|
| |||||
Return On Equity | 0.33 | 0.3182 |
|
|
For Novartis profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Novartis to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Novartis AG ADR utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Novartis's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Novartis AG ADR over time as well as its relative position and ranking within its peers.
Novartis |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.987 | Dividend Share 3.919 | Earnings Share 4.1 | Revenue Per Share 22.467 | Quarterly Revenue Growth 0.074 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Novartis AG ADR Current Valuation vs. Cash and Equivalents Fundamental Analysis
Novartis Current Valuation vs. Cash and Equivalents
Novartis | = | null |
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Novartis |
| = | 205.32 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Novartis Current Valuation vs Competition
Novartis AG ADR is rated top company in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 210.29 Billion. Novartis totals roughly 205.32 Billion in current valuation claiming about 98% of equities under Health Care industry.
Use Novartis in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novartis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novartis will appreciate offsetting losses from the drop in the long position's value.Novartis Pair Trading
Novartis AG ADR Pair Trading Analysis
The ability to find closely correlated positions to Novartis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novartis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novartis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novartis AG ADR to buy it.
The correlation of Novartis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novartis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novartis AG ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novartis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Novartis position
In addition to having Novartis in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
View All Next | Launch |
Check out Correlation Analysis. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |
To fully project Novartis' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Novartis AG ADR at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Novartis' income statement, its balance sheet, and the statement of cash flows.